Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mavorixafor

FDA-approved product (capsule, oral), marketed as Xolremdi.

Registered studies
15
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Mavorixafor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other immunostimulants
FDA pharmacologic class
CXC Chemokine Receptor 4 Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

15registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mavorixafor in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mavorixafor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

    NCT06858696 · start 2025-02-28

    Registered record
    Registry ID
    NCT06858696
    Conditions
    Hepatic Insufficiency
    Interventions
    Mavorixafor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-28
    Completion
    2026-01-12
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency
    InterventionMavorixafor
    PhasePhase 1
    Registry statusCompleted

  • Drug-Drug Interaction Potential of Mavorixafor

    NCT06914869 · start 2025-02-18

    Registered record
    Registry ID
    NCT06914869
    Conditions
    Healthy Participants
    Interventions
    Mavorixafor; Carbamazepine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-18
    Completion
    2025-05-19
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionMavorixafor; Carbamazepine; Efavirenz
    PhasePhase 1
    Registry statusCompleted

  • A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

    NCT06056297 · start 2024-06-06

    Registered record
    Registry ID
    NCT06056297
    Conditions
    Neutropenia
    Interventions
    Mavorixafor; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-06-06
    Completion
    2027-11
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia
    InterventionMavorixafor; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

    NCT04154488 · start 2021-10-16

    Registered record
    Registry ID
    NCT04154488
    Conditions
    Neutropenia
    Interventions
    Mavorixafor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2021-10-16
    Completion
    2024-08-27
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia
    InterventionMavorixafor
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

    NCT05103917 · start 2021-07-21

    Registered record
    Registry ID
    NCT05103917
    Conditions
    Triple Negative Breast Cancer
    Interventions
    X4P-001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2021-07-21
    Completion
    2023-05-21
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionX4P-001
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

    NCT04274738 · start 2020-04-30

    Registered record
    Registry ID
    NCT04274738
    Conditions
    Waldenstrom's Macroglobulinemia
    Interventions
    Mavorixafor; Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-04-30
    Completion
    2022-10-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenstrom's Macroglobulinemia
    InterventionMavorixafor; Ibrutinib
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

    NCT03995108 · start 2019-10-24

    Registered record
    Registry ID
    NCT03995108
    Conditions
    WHIM Syndrome
    Interventions
    Mavorixafor; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-24
    Completion
    2025-12-23
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWHIM Syndrome
    InterventionMavorixafor; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

    NCT02923531 · start 2016-12-07

    Registered record
    Registry ID
    NCT02923531
    Conditions
    Clear Cell Renal Cell Carcinoma
    Interventions
    X4P-001; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2016-12-07
    Completion
    2018-08-08
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma
    InterventionX4P-001; Nivolumab
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

    NCT03005327 · start 2016-12

    Registered record
    Registry ID
    NCT03005327
    Conditions
    WHIM Syndrome
    Interventions
    X4P-001
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12
    Completion
    2022-06-16
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWHIM Syndrome
    InterventionX4P-001
    PhasePhase 2
    Registry statusCompleted

  • X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

    NCT02823405 · start 2016-09-15

    Registered record
    Registry ID
    NCT02823405
    Conditions
    Melanoma
    Interventions
    X4P-001; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-09-15
    Completion
    2018-03-15
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionX4P-001; Pembrolizumab
    PhasePhase 1
    Registry statusCompleted

  • Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

    NCT02667886 · start 2016-04-27

    Registered record
    Registry ID
    NCT02667886
    Conditions
    Clear Cell Renal Cell Carcinoma
    Interventions
    X4P-001; axitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-04-27
    Completion
    2022-04-14
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma
    InterventionX4P-001; axitinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

    NCT02680782 · start 2016-01-12

    Registered record
    Registry ID
    NCT02680782
    Conditions
    Healthy
    Interventions
    X4P-001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-01-12
    Completion
    2016-02-28
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionX4P-001
    PhasePhase 1
    Registry statusTerminated

  • A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus

    NCT00361101 · start 2005-10

    Registered record
    Registry ID
    NCT00361101
    Conditions
    HIV Infections; X4 Tropic Virus
    Interventions
    AMD11070
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-10
    Completion
    2010-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; X4 Tropic Virus
    InterventionAMD11070
    PhasePhase 1
    Registry statusCompleted

  • Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

    NCT00089466 · start 2004-11

    Registered record
    Registry ID
    NCT00089466
    Conditions
    HIV Infections
    Interventions
    AMD11070
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-11
    Completion
    2009-01
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAMD11070
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

    NCT00063804

    Registered record
    Registry ID
    NCT00063804
    Conditions
    HIV Infections
    Interventions
    Ritonavir; AMD070
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-10
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; AMD070
    PhasePhase 1
    Registry statusCompleted